Johnson & Johnson’s single shot Coronavirus vaccine has been approved for use in the UK.
Johnson & Johnson’s single shot Covid
The vaccine, developed by the Janssen-controlled company, has been approved by the UK drug regulator and will be available later this year. The UK has ordered 20 million doses of the vaccine, which has been shown to be 67% effective in preventing moderate to severe Covid-19.
Also 85% effective in preventing severe illness or hospitalisation. Health and Social Care Secretary Matt Hancock said: “This is a further boost to the UK’s hugely successful vaccination programme, which has already saved over 13,000 lives and means we now have four safe and effective vaccines approved to help protect people from this terrible virus.
Virus blockade in England lifted further – but caution is key “As Janssen is a single dose vaccine, it will play an important role in the coming months as we redouble our efforts to encourage everyone to get the vaccines and potentially start a booster programme this year”. Britain has four vaccines approved for use in the largest vaccination programme in the country’s history.
Others are vaccines developed by Pfizer-Biontech, Oxford-Astrazeneca and Moderna. Do you think medicines and the health sector regulatory agency (MHRA) have brought forward the Janssen vaccine after concerns were raised in a link with extremely ra the blood clots. The clots are similar to those seen in a very small percentage of people who have the Oxford/AstraZeneca vaccine.
In April, the European Medicines Agency (EMA) said a warning about unusual blood clots with low platelets should be added to the product information for the vaccine. This followed eight cases of blood clots in more than seven million people vaccinated in the US. Johnson & Johnson said the vaccine works on multiple variants of Coronavirus.
In A clinical trial involving 43,783 people, published earlier this year, the level of protection against severe moderate infection of COVID-19 was found to be 72 per cent in the US study arm. It was 66 per cent in the Latin American trial arm and 57 per cent in the South African arm, where a mutant variant of the virus was dominant.